Lupin Limited today announced that its alliance partner Caplin Steriles Limited has received final approval from the United States Food and Drug Administration (U.S.FDA) for its Abbreviated New Drug Application (ANDA) Rocuronium Bromide Injection, via an exchange filing.
The approved dosages are 10mg/mL in 5 mL and 10 mL Multi-Dose Vials, to market a generic version of Zemuron Bromide Injection, 50 mg/5 mL and 100 mg/10 mL of Organon USA Inc.
Rocuronium Bromide Injection (RLD: Zemuron) had an annual sale of approximately USD 53 million in the U.S. (IQVIA MAT December 2022).
Read Also
Lupin’s alliance partner Caplin receives USFDA approval for Thiamine Hydrochloride Injection
Bombay HC Rejects Plea To Set Up ICCs For Advocates Under POSH Act, Says Law Doesn’t Apply Without Employer-Employee Relationship
Bombay HC Issues Contempt Notices To BMC Officials For Demolishing Petitioner’s Home Despite Assurances
₹122 Crore New India Co-operative Bank Scam: Jharkhand Gang Promised Hitesh Mehta 50% Returns; ₹15 Cr Withdrawn Under Pre-Planned Strategy; Reveals EOW Probe
'Historic Sword Of Maratha Sardar Raghuji Bhosale To Return To Maharashtra By July-End,' Says Minister Ashish Shelar
